Thursday, Pfizer Inc (NYSE:PFE) announced top-line Abrysvo vaccine efficacy and safety data for respiratory syncytial virus (RSV) in adults 60 years of age and older following a second season in ...

RSV vaccine sales from GSK and Pfizer have dropped significantly following revised CDC guidelines, narrowing the eligible age ...

On Monday, Pfizer Inc. (NYSE:PFE) stock is trading higher with a session volume of 31.16 million as per data from Benzinga ...

Presentations highlight momentum of Pfizer’s portfolio of infectious ... "As we approach another respiratory virus season, the importance of preventive vaccines and treatments to help keep ...

US FDA expands GSK's RSV vaccine approval to adults aged 50 to 59 In April, Pfizer said its vaccine ... including for cancer and respiratory syncytial virus (RSV). Moderna shares rose 8% to ...

In another positive development, Pfizer won a bid in a London court to invalidate two of GSK Plc’s GSK patents relating to its respiratory syncytial virus (RSV) vaccine. Also Read: UK Chooses ...

NEW YORK--(BUSINESS WIRE)--Pfizer Inc. (NYSE: PFE) will present data across its infectious disease portfolio at the upcoming IDWeek 2024 congress, held in Los Angeles from October 16-19, 2024.